SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia

por Appelbaum, Jacob, Arnold, Donald M., Kelton, John G., Gernsheimer, Terry, Jevtic, Stefan D., Ivetic, Nikola, Smith, James W., Nazy, Ishac
Publicado 2022

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

por Shih, Lauren, Othus, Megan, Schonhoff, Kelda, Shaw, Carole, Appelbaum, Jacob, Halpern, Anna B., Becker, Pamela S., Walter, Roland B., Estey, Elihu, Percival, Mary-Elizabeth
Publicado 2023

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report

por Appelbaum, Jacob, Wells, David, Hiatt, Joseph B., Steinbach, Gideon, Stewart, F. Marc, Thomas, Hannah, Nghiem, Paul, Kapur, Raj P., Thompson, John A., Bhatia, Shailender
Publicado 2018

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms

por Paras, Gabrielle, Othus, Megan, Schonhoff, Kelda, Shaw, Carole, Sorror, Mohamed, Halpern, Anna B., Appelbaum, Jacob, Hendrie, Paul, Walter, Roland B., Estey, Elihu H., Percival, Mary-Elizabeth M.
Publicado 2022

Context-specific synthetic T cell promoters from assembled transcriptional elements

por Appelbaum, Jacob, Wei, Jia, Mukherjee, Rithun, Ishida, Taylor, Rosser, James, Saxby, Chris, Chase, John, Carlson, Marc, Sather, Cassie, Rahfeldt, Wolfgang, Meechan, Michael, Baldwin, Michael, Flint, Lindsay, Spurrell, Cailyn, Gustafson, Joshua, Johnson, Adam, Jensen, Michael
Publicado 2023

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Gra...

por Godwin, Colin D., Rodríguez-Arbolí, Eduardo, Othus, Megan, Halpern, Anna B., Appelbaum, Jacob S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Oehler, Vivian G., Keel, Siobán B., Abkowitz, Janis L., Cooper, Jason P., Cassaday, Ryan D., Estey, Elihu H., Walter, Roland B.
Publicado 2022

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

por Halpern, Anna B., Rodríguez-Arbolí, Eduardo, Othus, Megan, Garcia, Kelsey-Leigh A., Percival, Mary-Elizabeth M., Cassaday, Ryan D., Oehler, Vivian G., Becker, Pamela S., Appelbaum, Jacob S., Abkowitz, Janis L., Orozco, Johnnie J., Keel, Siobán B., Hendrie, Paul C., Scott, Bart L., Ghiuzeli, M. Cristina, Estey, Elihu H., Walter, Roland B.
Publicado 2023